Section 3 of 6
Product information and disease description
301 evidence topics · 149 sources
Product description
Phase of product development
Regulatory status: Submission planned; U.S. accelerated approval application planned if the AMPLITUDE interim analysis, with data expected in early 2027, is positive
Launch
No evidence found.
Authorisation status in the European Union: not authorised
| Field | Quoted record |
|---|---|
| Investigational medicinal product | “VX-147 film-coated tablet” |
| Active substance | “Inaxaplin” |
| Authorisation status | “Not authorised” |
| Medicine status in the EU | “No EU-wide authorisation listed” |
Pivotal AMPLITUDE trial: full enrollment completed in 2026
Interim analysis timing: company guidance from January 2025 to November 2026
Interim analysis endpoints: company wording from March 2022 to September 2025
Interim analysis endpoints: registered primary endpoints
Interim analysis endpoint agreed with the FDA: eGFR slope
Breakthrough Therapy designation for APOL1-mediated FSGS, June 2022
PRIME designation for AMKD, May 2022
Rare Pediatric Disease designation for APOL1-mediated FSGS
EU orphan designation EU/3/22/2697, October 2022
| Field | Quoted record |
|---|---|
| Active substance | “Inaxaplin” |
| Intended use | “Treatment of apolipoprotein L1-mediated kidney disease” |
| Orphan designation status | “Positive” |
| EU designation number | “EU/3/22/2697” |
| Date of designation | “11/10/2022” |
| Sponsor | “Vertex Pharmaceuticals (Ireland) Limited” |
EU paediatric investigation plan EMEA-003368-PIP01-22, agreed October 2023
| Field | Quoted record |
|---|---|
| Active substance | “Inaxaplin” |
| Decision number | “P/0430/2023” |
| PIP number | “EMEA-003368-PIP01-22” |
| Pharmaceutical form | “Film-coated tablet” |
| Condition | “Treatment of apolipoprotein L1 (APOL1)-mediated kidney disease” |
| Route of administration | “Oral use” |
| Decision date | “27/10/2023” |
FDA orphan drug and Fast Track designations
No evidence found.
First-in-human study, June 2019 to January 2020
“The first-in-human study of inaxaplin (Study VX18-147-001 or Study 1) evaluated single ascending doses of 7.5 mg up to 50 mg and multiple ascending doses of 15 mg once daily, 15 mg twice daily, or 45 mg once daily in healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Study 1 was conducted at two sites in the United States (Madison, WI and Dallas, TX) between June 2019 and January 2020.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2a proof-of-concept results, December 2021
Pivotal phase 2/3 trial initiated, March 2022
Phase 3 portion and adolescent expansion, April 2024
Interim analysis cohort enrolled, September 2025
Phase 2b AMPLIFIED results, September 2026
Product information
Generic, brand name and therapeutic class of product
Generic name, chemical name, and identifiers
| Field | Quoted record |
|---|---|
| International nonproprietary name (Latin) | “inaxaplinum” |
| International nonproprietary name (English) | “inaxaplin” |
| Chemical name | “3-[5,7-difluoro-2-(4-fluorophenyl)-1H-indol-3-yl]-N- [(3S,4R)-4-hydroxy-2-oxopyrrolidin-3-yl]propanamide” |
| Functional description | “apolipoprotein L1 (APOL1) function inhibitor” |
| Molecular formula | “C21H18F3N3O3” |
| CAS registry number | “2446816-88-0” |
| INN list | “Proposed INN: List 125” |
Development codes: VX-147 and IXP
Brand name
No evidence found.
Manufacturer: Vertex Pharmaceuticals
| Field | Quoted record |
|---|---|
| Sponsor | “Vertex Pharmaceuticals Inc.” |
| Marketing authorisation holder of the investigational product | “VERTEX PHARMACEUTICALS, INCORPORATED” |
Therapeutic class: oral small molecule inhibitor of APOL1
Dosage forms and strengths
Investigational dosage form: 45 mg film-coated tablet for oral use
| Field | Quoted record |
|---|---|
| Product | “VX-147 film-coated tablet” |
| Pharmaceutical form | “FILM-COATED TABLET” |
| Route of administration | “ORAL USE” |
| Maximum daily dose | “45 mg milligram(s)” |
| Maximum total dose | “4860 mg milligram(s)” |
| Maximum duration of treatment | “108 week(s)” |
| Placebo | “VX-147, Coated Placebo Tablet” |
Tablet formulation development: relative bioavailability and food effect study
Commercial strengths and package sizes
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
AHFS classification
No evidence found.
WHO INN functional description: apolipoprotein L1 function inhibitor
EMA classification: apolipoprotein L1 inhibitors
| Field | Quoted record |
|---|---|
| Therapeutic area | “Uro-nephrology” |
Indication
Population of the pivotal AMPLITUDE trial: primary AMKD with severe proteinuria and no kidney disease-causing comorbidities
Indication named for a potential accelerated approval: patients with AMKD
Age range in AMPLITUDE: 10 to 65 years
Indications named in regulatory designations: APOL1-mediated FSGS (FDA) and AMKD (EMA)
| Field | Quoted record |
|---|---|
| Intended use | “Treatment of apolipoprotein L1-mediated kidney disease” |
Indication expansion studied in AMPLIFIED: AMKD with modest proteinuria or with type 2 diabetes
Pharmacology
Mechanism of action
Pharmacologic class: APOL1 function inhibitor
Oral small-molecule inhibitor of APOL1 channel function
“The underlying genetic cause of AMKD is a toxic gain-of-function in the APOL1 gene (G1 or G2) thought to enhance APOL1 channel function and damage glomerular cells (e.g., podocytes and endothelial cells) in response to an inflammatory trigger; the resulting cellular damage disrupts the glomerular filtration barrier, resulting in proteinuria, and often leads to accelerated loss of kidney function” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the mechanism of disease, targeted inhibition of APOL1 should inhibit glomerular damage, reduce proteinuria, and ultimately slow the progression of kidney disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaxaplin (previously known as VX-147) is an oral, small molecule inhibitor of APOL1 channel function that has been shown to reduce proteinuria in patients with AMKD in a phase 2a proof-of-concept study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Direct binding to APOL1 and inhibition of APOL1-mediated ion flux in cell models
Potency against APOL1 G0, G1, and G2 in channel, trypanolysis, and cell death assays
“we determined VX-147 potently inhibited the APOL1 ion channel with IC50 values of 2.3 nM for G0, 1.3 nM for APOL1 G1, and 1.1 nM for APOL1 G2 (Fig. 3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We found that VX-147 prevented APOL1-mediated T.b.b. death with essentially equivalent potencies to ion channel inhibition, with EC50 values of 2.0 nM for APOL1 G0, 2.1 nM for APOL1 G1, and 1.2 nM for APOL1 G2 (Fig. 3B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We saw complete inhibition of APOL1-dependent cell death using VX-147 with EC50 values of 4.3 nM for APOL1 G0, 2.0 nM for APOL1 G1, and 2.2 nM for APOL1 G2 (Fig. 3C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selectivity: off-target profiling
“VX-147 was previously shown to bind directly to purified, recombinant APOL1 and broad profiling across a large panel of potential off-targets did not identify any significant activity, indicating that the mechanism of action is due to direct inhibition of the APOL1 ion channel” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for limited on-target risk of APOL1 inhibition
“We reasoned an APOL1 ion channel inhibitor would be likely to have limited on-target safety risk, because there is a published report of an individual with no detectable APOL1 protein expression due to homozygous truncation mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This individual was healthy except for a sensitivity to trypanosome infection” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Potassium efflux as the proximal driver of APOL1-mediated cell death
Reversal of sodium import, potassium efflux, and downstream injury: independent study
“In HEK293 cells, we demonstrated that G1-mediated Na+ import/K+ efflux triggered activation of GPCR/IP3–mediated calcium release from the ER, impaired mitochondrial ATP production, and impaired translation, which were all reversed by VX-147.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our study provides the first detailed biochemical mechanism, to our knowledge, that explains how VX-147 protects kidney cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on these results, we conclude that the cytoprotective effects of VX-147 are not due to a decrease in G1 protein expression or translocation to the PM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blockade of APOL1-dependent calcium influx: independent study
Pharmacodynamics
Prevention of proteinuria in an interferon gamma-induced APOL1 G2 transgenic mouse model
Reversal of established proteinuria and eGFR decline with a close structural analog
“Compound 3 had a rapid effect at lowering the UACR (Fig. 4A and Supplementary Fig. 13).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of the UACR AUC following compound intervention revealed a 97% reduction over the 8 days of compound administration (Fig. 4B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In transgenic APOL1 mouse models, we used Compound 3, a close analog of VX-147 with comparable potency and selectivity, to show that blockage of the APOL1 channel can both prevent and reverse APOL1-dependent proteinuria as well as preserve glomerular integrity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Podocyte injury and proteinuria in APOL1 G1 transgenic mice: independent study
“Within 48 hours, IFN-γ–treated mice developed significant proteinuria, which was almost completely attenuated with cotreatment with VX-147 (Figure 10, A and C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, these injury phenotypes were prevented by VX-147 treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preeclampsia phenotype in pregnant APOL1 G2/G2 transgenic mice
Projected inhibition of APOL1 ion flux at 15 mg and 45 mg once daily
Onset and offset of proteinuria reduction in participants with APOL1-mediated FSGS
Electrocardiographic effects in healthy adults
“There was no evidence of effects of inaxaplin on ECG parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no participants with a maximum QT interval corrected by Fridericia’s formula (QTcF; calculated from ECG assessments) interval >480 msec.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No participants in the SAD or MAD cohorts had a QTcF interval increase >60 msec.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum creatinine, lipids, and leukocyte counts in healthy adults
“Specifically, mean serum creatinine concentrations, serum lipid profile (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride concentrations), and leukocyte counts were similar between the inaxaplin and placebo groups for all timepoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics
Dose proportionality, half-life, and renal clearance in healthy adults
“The PK of inaxaplin was generally dose proportional, and the variability in PK parameters was generally low and did not appear to change across the dose range (online Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Half-life was consistent across both studies ranging from approximately 13.3 to 22.9 h, which supports once daily dosing (online Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Renal clearance was a minor excretion pathway for inaxaplin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Steady-state exposure at 45 mg once daily and exposure margin at 120 mg once daily
Relative bioavailability and food effect of a test tablet formulation
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Renal impairment: minor renal elimination
Renal impairment: single-dose study in severe renal impairment
Renal function range enrolled in AMPLITUDE
Hepatic impairment: single-dose study in mild or moderate hepatic impairment
Pediatric population: adolescents added to the phase 3 portion of AMPLITUDE
Pediatric population: acceptability of the tablet formulation
Pregnancy and childbearing potential: exclusion from the phase 1 studies
“In both studies, we enrolled healthy men and women of non-childbearing potential who were at least 18 years of age with body weight of >50 kg and body mass index (BMI) 18.0 to 32.0 kg/m2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A limitation of these studies, like most phase 1 studies, is that participants were predominantly men (owing to exclusion of women of childbearing age).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Contraception requirements in the phase 2a study
Drug/Drug, drug/disease interactions
Effects of other drugs on Inaxaplin
CYP3A4 and P-glycoprotein substrate
Rifampin and itraconazole drug interaction study in healthy adults
Strong CYP3A and P-gp inducer: rifampin
Strong CYP3A4 and P-gp inhibitor: itraconazole; moderate CYP3A4 inhibitor: cyclosporine
Restricted medications and foods in the phase 2a study
| Restriction | Start | Stop |
|---|---|---|
| CYP3A4 inhibitors or inducers | “None allowed within 14 days before the first dose of the study drug” | “Completion of Safety Follow-up Visit assessments” |
| Grapefruit and related fruits | “7 days before first dose of study drug” | “Until last PK sample is taken” |
QT-prolonging concomitant medications excluded from AMPLITUDE
Effects of Inaxaplin on other drugs
Sensitive CYP3A4 substrate: midazolam
“We assessed the potential of inaxaplin to either induce or inhibit CYP3A4 enzymes in Study 1 by measuring the effect of inaxaplin administration on serum concentrations of midazolam, a sensitive CYP3A4 substrate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no clinically significant PK drug-drug interactions between inaxaplin and midazolam (online Table S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaxaplin is not a clinically significant inhibitor or inducer of CYP3A4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
In vitro CYP3A4 induction and removal of the CYP3A substrate restriction
Combined oral contraceptives: ethinyl estradiol and levonorgestrel
Dosing and administration
Dosage
Phase 3 dose: 45 mg once daily selected by the independent data monitoring committee
Doses compared in the phase 2 portion of AMPLITUDE: 15 mg and 45 mg once daily
“The safety and efficacy of inaxaplin at 15 mg once daily and 45 mg once daily (which is in the lower range of doses explored in these phase 1 studies) is currently being evaluated in a randomized, double-blind, placebo-controlled, phase 2/3 adaptive trial in adults with AMKD (ClinicalTrials.gov number, NCT05312879).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2a regimen: 15 mg once daily for 2 weeks, then 45 mg once daily for 11 weeks
Rationale for the phase 2a doses
Maximum daily dose, total dose, and treatment duration in the EU trial record
| Field | Quoted record |
|---|---|
| Maximum daily dose | “45 mg milligram(s)” |
| Maximum total dose | “4860 mg milligram(s)” |
| Maximum duration of treatment | “108 week(s)” |
Administration
Oral film-coated tablet
| Field | Quoted record |
|---|---|
| Investigational medicinal product | “VX-147 film-coated tablet” |
| Pharmaceutical form | “FILM-COATED TABLET” |
| Route of administration | “ORAL USE” |
Administration instructions in the phase 2a study
Missed doses in the phase 2a study
Access and distribution
Vertex-sponsored no-cost APOL1 genetic testing: Labcorp program
Vertex-sponsored no-cost APOL1 genetic testing: Natera Renasight program
Vertex-sponsored no-cost APOL1 genetic testing: Arkana Laboratories program
Vertex-sponsored genotyping study for clinical trial referral
Genotype assay required for trial eligibility
Companion diagnostic
No evidence found.
Specialty pharmacy or distribution network
No evidence found.
Co-prescribed/Concomitant therapies
Required background ACE inhibitor or ARB in AMPLITUDE
Permitted concomitant kidney therapies in AMPLITUDE at a stable dose
Excluded concomitant medications in AMPLITUDE: QT-prolonging drugs
Inaxaplin added to standard of care in AMPLITUDE
Background therapy in AMPLIFIED: optimized standard of care
Background therapy in the phase 2a study: stable standard-care medications
Effect of Inaxaplin on quality measures
HEDIS Kidney Health Evaluation for Patients With Diabetes (KED)
Product-specific effect on quality measures
No evidence found.
Product comparison
APOL1-directed and other investigational therapies for AMKD: review table
“Antisense oligonucleotide therapy is in phase 1 trials because of studies in mice showing a dose-dependent reduction in liver and kidney APOL1 mRNA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“a recent small molecule inhibitor, MZE829, attempts to phenocopy this protective variant in a phase 1 study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MZE829 (Maze Therapeutics): oral dual-mechanism APOL1 inhibitor, phase 2 HORIZON interim results
MZE829: HORIZON enrollment completed and pivotal trial planned for the first half of 2027
Competitive positioning of inaxaplin and MZE829
AZD2373 (AstraZeneca): subcutaneous APOL1-directed therapy, phase 2b APPRECIATE trial
| Field | Quoted record |
|---|---|
| Sponsor | “AstraZeneca” |
| Status | “Active, not recruiting” |
| Enrollment (actual) | “63” |
| Primary completion (estimated) | “2027-10-04” |
AZD2373: APOL1 genotyping clinical trial assay used to select participants
AZD2373: phase 1 studies in healthy participants of African ancestry
VX-840 and other Vertex APOL1 inhibitors
Approved therapies directed at the cause of AMKD
Place of product in therapy
Disease description
Definition and etiology
Disease definition: nondiabetic kidney disease in a person with two APOL1 risk variants
“AMKD is diagnosed when an individual with a high-risk APOL1 genotype develops nondiabetic kidney disease. There is no established glomerular filtration rate (GFR) cutoff to diagnose AMKD. Proteinuria (urine albumin to creatinine ratio >30 mg/g) is often present but is not a requirement for the diagnosis of AMKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“APOL1-associated nephropathy reflects a spectrum of kidney diseases caused by APOL1 risk variants. It can be superimposed on other forms of kidney disease, but often, it presents as glomerulosclerosis with accompanying tubulointerstitial and vascular changes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Terminology: APOL1 kidney disease at the 2024 KDIGO Controversies Conference, and ICD-10-CM codes
“The terms APOL1-mediated or -associated kidney disease lacked universal support largely because APOL1 high-risk genotypes are probabilistic—not deterministic—risk factors for developing kidney disease, and most people with high-risk APOL1 genotypes do not develop clinically apparent kidney disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The term APOL1 kidney disease received the highest support for describing kidney pathologies associated with the G1 and G2 variants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“New International Classification of Disease-10th Edition-Clinical Modification codes for APOL1-mediated kidney disease (AMKD) and family history of AMKD in the United States provide great hope to the millions of people with recent African ancestry and chronic kidney disease worldwide. In the past, vague diagnosis codes forced misclassification of many such patients, especially nondiabetic persons of African ancestry.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Genetic cause: G1 and G2 variants with a recessive two-risk-allele genotype
“In people of African ancestry, 2 apolipoprotein L1 gene (APOL1) variants have been identified as causing increased risk of progressive chronic kidney disease (CKD) compared with non–high-risk APOL1 variants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The risk variants, labelled G1 (2 amino acid substitutions) and G2 (2 deletions), confer resistance to infection from certain subspecies of the trypanosome parasite. Combinations of 2 risk variants (G1/G1, G2/G2, or G1/G2) are referred to as high-risk genotypes for the development or progression of CKD, and they are associated with a spectrum of kidney diseases of both continuous and categorical disease phenotypes (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is emerging evidence that a single risk allele (G1/G0 or G2/G0) may also confer risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The risk of kidney disease associated with the APOL1 G1 and G2 alleles follows a recessive inheritance pattern. Individuals who are heterozygous for a G1 or G2 variant (G1/G0 or G2/G0) are resistant to African sleeping sickness but do not have increased risk of kidney disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Evolutionary origin: positive selection for resistance to African trypanosomiasis
“The two APOL1 variants are common in African chromosomes but absent from European chromosomes and both reside within haplotypes that harbor signatures of positive selection. ApoL1 is a serum factor that lyses trypanosomes. In vitro assays revealed that only the kidney disease-associated ApoL1 variants lysed Trypanosoma brucei rhodesiense.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The G1 and G2 variants of the APOL1 gene restored immune protection against the novel T brucei strains and underwent positive selection in West Africa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These high-risk APOL1 variants are hypothesized to have evolved more than 10,000 years ago and rose to a high frequency in Africa because they provided protection against lethal African sleeping sickness due to Trypanosoma brucei rhodesiense and gambiense infections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phenotype spectrum: FSGS, hypertension-attributed kidney disease, HIVAN, COVAN, lupus nephritis, and sickle cell nephropathy
“APOL1 high-risk genotypes have been associated with several kidney diseases, including FSGS, HIV-associated nephropathy, hypertension-attributed ESKD, lupus nephritis, and sickle cell disease nephropathy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As discussed above, high-risk APOL1 genotypes have been associated with a spectrum of kidney disease phenotypes: vascular disease (hypertension-attributed kidney failure), diseases of the podocyte, and infectious etiologies such as HIV- and COVID-associated nephropathy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“APOL1 risk variants increase the risk of hypertension-attributed ESKD (H-ESKD; 7- to 11-fold), FSGS (17-fold), HIV-associated nephropathy (HIVAN; 29- to 89-fold), nondiabetic CKD (2- to 4-fold), and other kidney disease manifestations. APOL1 does not appear to affect risk for developing IgA nephropathy or diabetic nephropathy (but does have some influence on progression in patients with diabetes and proteinuric kidney disease).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Kidney diseases in the spectrum include FSGS with and without nephrotic-range proteinuria, HIV-associated nephropathy (HIVAN), interferon-associated FSGS, severe lupus nephritis (LN), sickle cell nephropathy, and solidified glomerulosclerosis with low-level proteinuria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FSGS, hypertension-attributed ESKD, and HIVAN: odds ratios in the case-control studies
“Here we show that in African-Americans, focal segmental glomerulosclerosis (FSGS) and hypertension-attributed end-stage kidney disease (H-ESKD) are associated with two independent sequence variants in the APOL1 gene on chromosome 22 [FSGS odds ratio = 10.5 (95% CI 6.0–18.4); H-ESKD odds ratio = 7.3 (95% CI 5.6–9.5)].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a recessive model, APOL1 variants conferred seventeenfold higher odds (95% CI 11 to 26) for focal segmental glomerulosclerosis (FSGS) and twenty-nine-fold higher odds (95% CI 13 to 68) for HIV-associated nephropathy (HIVAN).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
COVID-19-associated collapsing glomerulopathy (COVAN)
“This case series included six Black patients with COVID-19 (four men, two women), mean age 55 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All six patients had an APOL1 high-risk genotype. Five patients needed dialysis (two of whom died); one partially recovered without dialysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 23 patients with COVID-19–associated collapsing glomerulopathy were median age 57 years (range, 35–72), included 16 men, and were predominantly (91%) Black.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 17 patients genotyped, 16 (94%) were high-risk APOL1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lupus nephritis: APOL1 and lupus nephritis-attributed ESKD
“The G1/G2 risk alleles were strongly associated with SLE-ESRD, with 25% of cases and 12% of controls having 2 nephropathy alleles” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The age-, sex-, and admixture-adjusted population attributable risk for ESRD among patients with G1/G2 polymorphisms was 0.26, compared to 0.003 among European American patients. The mean time from SLE diagnosis to ESRD development was ~2 years earlier among individuals with APOL1 risk genotypes (P = 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Second hits and modifiers: interferon, viral infection, and the p.N264K variant
“The two-hit hypothesis suggests that a high-risk APOL1 genotype could act as a first hit, but a second hit, such as modifier genes, HIV infection, SLE, or other comorbidity, may be required to initiate nephropathy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Even among individuals with a high-risk genotype, having 2 APOL1 risk alleles does not necessarily lead to development of CKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nongenetic second hits resulting in glomerular disease include high interferon states, viral infections (HIV and COVID-19), exposure to alpha, beta, or gamma interferon, and APOL1 overexpression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Expression of APOL1 is regulated by cytokines (mostly by interferon), inflammation, hypoxia/ischemia, viruses, and nucleic acids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The APOL1 p.N264K variant was recently found to genetically and almost completely negate the effect of G2 risk alleles to levels comparable to G0, and this observation has been replicated in subsequent studies, making APOL1 p.N264K the most robust genetic modifier of APOL1 G2 to date.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unpredictability of disease among genotype carriers
“Despite the strong association between having a high-risk genotype and increased risk of kidney disease, it is not possible to predict which individuals with a high-risk genotype will develop CKD, idiopathic FSGS, hypertension-attributed kidney disease, HIV-1–associated nephropathy (HIVAN), or earlier failure of a kidney transplant from a donor with an APOL1 high-risk genotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of APOL1-mediated kidney disease
United States, 2023: kidney failure by race in the US Renal Data System
“ESKD affects approximately 750,000 people in the United States and represents a major health disparity, with incidence approximately three-fold higher among Black people than among White people.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“According to the United States Renal Data System 2020 Annual Data Report, 30% of patients with end-stage kidney disease (ESKD) in the US are Black individuals, although they comprise only 13% to 14% of the population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry data: no AMKD diagnosis in the US Renal Data System
“The lack of an AMKD diagnosis in the US Renal Data System and international registries has had profound effects on public health, confusing the epidemiology of kidney failure and delaying research for more accurate diagnoses and treatments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fraction of disease attributable to the high-risk genotype
“Rates of many types of severe kidney disease are much higher in Black individuals than most other ethnic groups. Much of this disparity can now be attributed to genetic variants in the apoL1 (APOL1) gene found only in individuals with recent African ancestry.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Penetrance: lifetime risk of CKD, kidney failure, FSGS, and HIVAN among genotype carriers
“Studies in African American individuals indicate that approximately 15%–20% of individuals with 2 APOL1 risk alleles develop CKD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 15% of individuals with an APOL1 high-risk genotype will develop kidney failure, and a smaller fraction will develop FSGS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with a high-risk APOL1 genotype have been estimated to have a 15% to 30% lifetime risk of developing ESKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The basis of this variable penetrance is currently unknown.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lifetime risk of clinically significant kidney disease for individuals with two APOL1 risk alleles remains uncertain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Some estimates pose that the lifetime probability of developing ESKD for carriers of the high-risk genotype may be up to 15%, a number that requires refinement (51).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Atherosclerosis Risk in Communities study: incident CKD and ESKD in middle-aged Black adults
“Carrying two risk alleles associated with a 1.49-fold increased risk of CKD (95% CI=1.02 to 2.17) and a 1.88-fold increased risk of ESRD (95% CI=1.20 to 2.93) compared with zero or one risk allele; associations persisted after adjusting for European ancestry.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 3067 African-American participants free of CKD at baseline, 190 (6.2%) participants developed CKD. The overall incidence rate of CKD was 7.94 events/1000 person-years among participants carrying zero APOL1 risk alleles, 8.60 events/1000 person-years among participants carrying one risk allele, and 11.64 events/1000 person-years among participants carrying two risk alleles (Table 2)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among participants with follow-up for ESRD events through 2008, 114 (3.7%) participants experienced an ESRD event over a median follow-up of 19.7 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Atherosclerosis Risk in Communities study: healthy middle-aged adults followed for 25 to 30 years
“There were 5,075 Whites (86%), 701 Blacks carrying the low-risk APOL1 genotype (12%), and 110 Blacks carrying the high-risk APOL1 genotype (2%). The mean age at baseline was 53 ± 6 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The odds of developing CKD stage 3a or worse were not different between low-risk and high-risk APOL1 group in both unadjusted and adjusted models (P = 0.26 and P = 0.39, respectively). At last follow-up, <5% developed ESKD, and 45% of individuals either died or reached ESKD with no difference in outcomes between the groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Jackson Heart Study: incident albuminuria, CKD, and ESKD
“Of 2,300 participants, 41.3% had zero, 45.1% had 1, and 13.6% had 2 APOL1 risk variants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with participants with zero APOL1 risk variants, those with 2 alleles had an increased risk for incident albuminuria (adjusted HR [aHR], 1.88; 95% CI, 1.04 to 3.40), ESKD (aHR, 9.05; 95% CI, 1.79 to 45.85), incident CKD (aHR, 1.65; 95% CI, 1.06 to 2.57)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CARDIA study: incident albuminuria in young adults
“Mean age was 35 years, mean eGFRcys was 107 ml/min per 1.73 m2, and 13.2% of blacks had two APOL1 alleles. The incidence rate per 1000 person-years (95% confidence interval) for albuminuria over 15 years was 15.6 (10.6–22.1) for high-risk blacks, 7.8 (6.4–9.4) for low-risk blacks, and 3.9 (3.1–4.8) for whites. Compared with whites, the odds ratio (95% confidence interval) for incident albuminuria was 5.71 (3.64–8.94) for high-risk blacks and 2.32 (1.73–3.13) for low-risk blacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States, 2008 to 2018: incidence of FSGS-attributed kidney failure in the US Renal Data System
“The mean annual period prevalence and incidence rates of FSGS-attributed kidney failure from 2008 to 2018 were 87.6 and 7.5 per million in the US population, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority were White (61.8%) or Black (32.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of APOL1-mediated kidney disease
United States: high-risk genotype frequency among Black Americans
“Based on cohort and cross-sectional studies in the United States, the estimated allelic frequency among African Americans is 20%–22% for G1 and 13%–15% for G2, with approximately 10%–15% having an APOL1 high-risk genotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among Black individuals in the US, the G1 allele frequency is 22% and G2 allele frequency is 13%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 13% of Black individuals in the US (more than 5 million people) have a high-risk APOL1 genotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the MVP cohort, 15,604 (12.8%) had two APOL1 HR variants, of which 582 (0.5%) also had APOL1 p.N264K.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Allele frequencies of the G1 and G2 alleles were 22% and 13%, respectively (Table 1). Overall, 13.2% of the study sample carried two APOL1 risk alleles (G1/G1, G1/G2, or G2/G2), whereas 45.4% and 41.4% carried one (wild type [WT]/G1 or WT/G2) or zero (WT/WT) risk alleles, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: estimated share of the Black population affected
“Approximately 10%–15% of the Black population has a high-risk APOL1 genotype” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“we can estimate that up to 3% of the Black population will be affected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
West Africa and sub-Saharan Africa: high-risk genotype frequency
“Frequencies of APOL1 high-risk genotypes are highest in West Africa, with up to 50% in Southeastern Nigeria, 37% in Central Ghana, and 25% in Southwestern Nigeria (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given that more than 100 million people in Sub-Saharan Africa may have 2 APOL1 high-risk alleles, the potential burden of APOL1 kidney disease in this region is catastrophically high.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Human Health and Heredity in Africa (H3Africa) Kidney Disease Research Network studied 8,355 participants from Ghana and Nigeria: 4,712 participants with CKD stages 2–5, 866 participants with biopsy proven glomerular diseases, and 2777 controls (eGFR ≥90 ml/min/1.73m2 without proteinuria).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 43.0% and 29.7% participants carried 1 and 2 APOL1 risk variants, respectively (Table S4). The G1 haplotype was more frequent (40.7%) than the G2 haplotype (13.9%). The prevalence of APOL1 high-risk carriers was higher among persons with CKD compared to those without CKD (31.6% vs. 25.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Africa, the APOL1 risk alleles are heavily concentrated in West Africa, and they are found at lower frequencies in eastern and southern Africa (15). For example, some groups within Nigeria or Ghana have combined risk variant allele frequencies that may exceed 50% (with high-risk genotypes of 25%), whereas individuals in Ethiopia, Sudan, and Somalia have very low probability of having two APOL1 risk variants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
The Americas: high-risk genotype frequency in 111 populations
“we found elevated frequencies of the APOL1 haplotype in African-American, sub-Saharan African, and Western African populations (11 to 32%). However, we also found other populations with elevated frequencies, including Jamaican, Barbadian, Grenadian, and Brazilian from Salvador (>10 to 22%); Trinidadian, Panamanian, Honduran, Haitian, Garifunan, and Palenque (>5 to 10%); and Guyanese, Dominican, Peruvian, Belizean, and Native American (1 to 5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Europe: high-risk genotype in unexplained kidney failure in the UK 100,000 Genomes Project
“The study recruited 218 patients with uKF onset before age 50 years from the United Kingdom's 100,000 Genomes Project.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals with recent African ancestry, high-risk APOL1 genotypes were significantly more common in those with uKF (52% vs 8.4% in those without uKF; P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Key areas of need include prevalence data for Black populations in the Caribbean, Brazil, the United Kingdom, Belgium, France, Sub-Saharan Africa, and any populations originating after dislocation by the diaspora (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
High-risk genotype among Black patients with nondiabetic CKD, FSGS, and hypertension-attributed ESKD
“The high-risk genotypes are found in approximately 16%–23% of Black people with nondiabetic CKD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“40%–60% of those with primary FSGS have 2 APOL1 risk alleles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A high-risk APOL1 genotype is present in about 75% of Black patients with FSGS (1,33).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, approximately 50% of Black patients with hypertension-attributable ESKD have a high-risk APOL1 genotype (1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
High-risk genotype among people referred for APOL1 genotyping or kidney genetic testing
“Of 15,181 patients, 1035 (6.8%) had high-risk APOL1 genotypes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Considering APOL1 genotypes, 25.6% of patients in the genetic African ancestry cluster had high-risk APOL1 genotypes (n = 944), 39.5% were single risk allele carriers (n = 1453), and 34.8% had G0/G0 (n = 1281; Table 2 and Supplementary Figure S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States, 2008 to 2018: prevalence of FSGS-attributed kidney failure in the US Renal Data System
Company estimates: Vertex Pharmaceuticals statements of the affected population in the United States and Europe, 2024 to 2026
Natural history, survival, and mortality
Penetrance: lifetime risk of kidney failure with a high-risk genotype
“Even among individuals with a high-risk genotype, having 2 APOL1 risk alleles does not necessarily lead to development of CKD. Approximately 15% of individuals with an APOL1 high-risk genotype will develop kidney failure, and a smaller fraction will develop FSGS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the strong association between having a high-risk genotype and increased risk of kidney disease, it is not possible to predict which individuals with a high-risk genotype will develop CKD, idiopathic FSGS, hypertension-attributed kidney disease, HIV-1–associated nephropathy (HIVAN), or earlier failure of a kidney transplant from a donor with an APOL1 high-risk genotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with a high-risk APOL1 genotype have been estimated to have a 15% to 30% lifetime risk of developing ESKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The basis of this variable penetrance is currently unknown.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals with high-risk APOL1 genotypes, the lifetime risk of developing kidney failure is ∼15%, indicating that other genetic variants or nongenetic modifiers likely contribute substantially to an individual patient’s risk of progressive kidney disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression in established CKD: AASK and CRIC cohorts
“In the AASK study, the primary outcome occurred in 58.1% of the patients in the APOL1 high-risk group and in 36.6% of those in the APOL1 low-risk group (hazard ratio in the high-risk group, 1.88; P<0.001). There was no interaction between APOL1 status and trial interventions or the presence of baseline proteinuria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the patients with diabetes, the eGFR slope (as measured in milliliters per minute per 1.73 m2 per year) was −1.5 among white patients, −2.7 among black patients in the APOL1 low-risk group, and −4.3 among black patients in the APOL1 high-risk group. Among the patients without diabetes, the corresponding eGFR slopes were −0.7, −1.0, and −2.9.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trajectory of eGFR decline in hypertension-attributed CKD
“Over a median follow-up of 9 years, 24.0% of participants experienced steady eGFR decline, 25.9% had an unsteady decline, 25.6% were steady and stable, and 24.6% were unsteady but stable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The APOL1 high–risk group was associated with a greater odds for the steady decline pattern than the APOL1 low–risk group (unadjusted odds ratio, 2.45; 95% confidence interval, 1.62 to 3.69). This association remained significant after adjusting for demographic factors, baseline eGFR, urine protein-to-creatinine ratio, treatment assignment, and follow-up time (adjusted odds ratio, 1.59; 95% confidence interval, 1.00 to 2.52).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with the high-risk genotypes were 1.72-fold more likely to develop incident proteinuria compared with those with the low-risk genotypes (95% confidence interval, 1.27 to 2.32), independent of age, sex, ancestry, baseline eGFR, baseline systolic BP, and randomized treatment groups. Although eGFR declined faster after the onset of proteinuria, this rate did not differ significantly by APOL1 risk status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world progression in genetically confirmed AMKD
Age at kidney failure and time to dialysis: company and laboratory statements
FSGS: faster progression to kidney failure
“FSGS associated with two APOL1 risk alleles associated with earlier age of onset (P = 0.01) and faster progression to ESRD (P < 0.01) but similar sensitivity to steroids compared with other subjects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The hazard ratio for progression was 2.3 (95% CI 1.43, 4), and median survival was 5 yr for subjects with 2 APOL1 risks alleles, compared with 13 yr for subjects with 0 or 1 APOL1 risk allele.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
General population: incident CKD and kidney failure in ARIC
“Carrying two risk alleles associated with a 1.49-fold increased risk of CKD (95% CI=1.02 to 2.17) and a 1.88-fold increased risk of ESRD (95% CI=1.20 to 2.93) compared with zero or one risk allele; associations persisted after adjusting for European ancestry. Among participants who developed CKD, those participants with two risk alleles were more likely to progress to ESRD than their counterparts with zero or one risk allele (HR=2.22, 95% CI=1.01 to 4.84).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Black race and APOL1 high-risk status were associated with faster eGFR decline (P<0.001 for each). However, we detected substantial overlap among the groups: median (10th–90th percentile) unadjusted eGFR decline was 1.5 (1.0–2.2) ml/min per 1.73 m2 per year for whites, 2.1 (1.4–3.1) ml/min per 1.73 m2 per year for blacks with APOL1 low-risk status, and 2.3 (1.5–3.5) ml/min per 1.73 m2 per year for blacks with APOL1 high-risk status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Young adults: incident albuminuria and eGFR decline in CARDIA
“The incidence rate per 1000 person-years (95% confidence interval) for albuminuria over 15 years was 15.6 (10.6–22.1) for high-risk blacks, 7.8 (6.4–9.4) for low-risk blacks, and 3.9 (3.1–4.8) for whites.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjustment, high-risk blacks had a 0.45% faster yearly eGFRcys decline over 9.3 years compared with whites.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Children with APOL1-associated glomerular disease
“In the United States, children having a high-risk APOL1 genotype are reportedly at increased risk for early onset CKD.13,46 Findings suggest a common natural history for children with APOL1-associated glomerular disease, where children with high-risk genotypes have a more aggressive form of glomerular disease, which may relate to high rates of FSGS and prematurity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prognostic heterogeneity among high-risk genotype carriers with preserved eGFR
“APRS achieved a time-dependent area under the receiver operating characteristic curve (tAUC) of 86.5%, outperforming the Kidney Failure Risk Equation (66.1%) and polygenic risk scores, with 10-year event rates of 62.5% versus 3.3% across risk quintiles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
COVID-19-associated collapsing glomerulopathy: short-term outcomes
“At follow-up, 19 (86%) patients were alive, and 15 (68%) were dialysis free, including seven of 14 who initially required dialysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 36% achieved partial remission of proteinuria, 32% had no remission, and 32% reached combined end points of ESKD or death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: death before kidney failure and all-cause mortality by genotype
“Over a median follow-up of 9 years, 77 patients (11.1%) died before reaching the composite renal outcome, 204 (29.4%) received a diagnosis of end-stage renal disease, and 288 (41.6%) reached the composite renal outcome (Table 2). APOL1 status was not significantly associated with death before a diagnosis of end-stage renal disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over a mean follow-up of 5.1 years, APOL1 high-risk Blacks had a 2.67-fold higher risk for ESRD compared with low-risk Blacks (95% confidence interval [CI] = 1.05–6.79) in models adjusted for age and sex. This association was no longer significant upon further adjustment for baseline eGFRCrCys and albuminuria (hazard ratio [HR] = 1.08; 95% CI = .39–2.96). Rate of hospitalizations and risks of mortality and incident CKD did not differ significantly by APOL1 genotype status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a recessive genetic model adjusted for demographics, comorbidities, and kidney measures, there were no significant associations between APOL1 kidney-risk genotypes and death or the composite outcome of incident cardiovascular disease, which included coronary heart disease, stroke, myocardial infarction, and heart failure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Kidney transplantation: allograft survival with kidneys from high-risk genotype donors
“Twenty-two of 136 transplanted kidneys (16%) were from donors with two APOL1 nephropathy risk variants. Twenty five grafts failed; eight (32%) had two APOL1 risk variants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Kidneys from AA deceased donors harboring two APOL1 risk variants failed more rapidly after renal transplantation than those with zero or one risk variants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combined analysis of 1153 DDKTs from AA donors revealed donor APOL1 high-risk genotype (HR 2.05; p=3×10−4), older donor age (HR 1.18; p=0.05), and younger recipient age (HR 0.70; p=0.001) adversely impacted allograft survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A competing risk analysis revealed that APOL1 impacted renal allograft survival, but not recipient survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the United States, living donors with APOL1 high-risk genotypes more often develop advanced CKD post donation,84 and receipt of deceased donor kidneys from APOL1 high-risk genotype donors are associated with more rapid graft failure.85–87 Results are mixed,88–90 but recipients with high-risk APOL1 genotypes may also have reduced graft survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Living kidney donors: kidney function after donation
“Sixty-eight Black donors (15.3%) had APOL1 high-risk genotypes (G1/G1, G2/G2, or G1/G2). Home-based research study visits occurred a median (IQR) of 18.5 (16.9-20.5) years after donation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Black kidney donors with APOL1 high-risk genotypes had a higher risk of developing an eGFR of less than 45 mL/min/1.73 m2 than Black kidney donors without APOL1 high-risk genotypes (relative risk, 2.31; 95% CI, 1.16-4.61; P = .02) (after adjustment for predonation eGFR: relative risk, 1.91; 95% CI, 0.90-4.03; P = .09).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At a median of 12 years after donation, donors with the APOL1 high-risk genotype had lower eGFR (57±18 versus 67±15 ml/min per 1.73 m2; P=0.02) and faster decline in eGFR after adjusting for predonation eGFR (1.19; 95% confidence interval, 0 to 2.3 versus 0.4; 95% confidence interval, 0.1 to 0.7 ml/min per 1.73 m2 per year, P=0.02). Two donors developed ESRD; both carried the APOL1 high-risk genotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
APOLLO: prospective study of transplant outcomes by donor and recipient genotype
“The National Institutes of Health (NIH)–sponsored APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) is prospectively assessing kidney allograft survival from donors with recent African ancestry based on donor and recipient APOL1 genotypes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary objective of APOLLO is determining whether the presence of APOL1 renal-risk genotypes in deceased-donors is associated with death-censored renal allograft survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“APOLLO aims to enroll all eligible kidney donors and kidney transplant recipients from U.S. transplant programs. This effort includes 260 academic and community-based programs with kidneys recovered from 58 OPOs (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Normal function of APOL1: trypanolytic pore-forming protein
“The APOL1 gene encodes an innate immune pore-forming protein that inserts into the trypanosome’s lysosomal membrane, inducing osmotic stress and ultimately lysing the trypanosome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The G1 and G2 variants of the APOL1 gene restored immune protection against the novel T brucei strains and underwent positive selection in West Africa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gain-of-function cation channel activity of the G1 and G2 variants
“APOL1 protein can act as an ion channel (pore) in trypanosome and eukaryotic cells.26,49–51 The G1 and G2 variants of APOL1 alter the normal pore-forming function of the APOL1 protein, leading to increased pore activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In cell-based models, G0 is generally nontoxic, whereas G1 and G2 express toxic, gain-of-function variants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recent experimental evidence suggests that the G1 and G2 variants may cause kidney injury by increased transport of monovalent cations—similar to the mechanism by which G1 and G2 provide resistance to T brucei.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In HEK293 cells, we demonstrated that G1-mediated Na+ import/K+ efflux triggered activation of GPCR/IP3–mediated calcium release from the ER, impaired mitochondrial ATP production, and impaired translation, which were all reversed by VX-147.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Together, these results establish APOL1-mediated Na+/K+ transport as the proximal driver of APOL1-mediated kidney disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Human genetic evidence: the p.N264K variant blocks pore function
“A different APOL1 variant, p.N264K, reduced the risk of CKD and ESKD among carriers of APOL1 HR variants to levels comparable with individuals with APOL1 low-risk variants in an analysis of 121,492 participants of African ancestry from the Million Veteran Program (MVP). Functional genetic studies in cell models showed that APOL1 p.N264K blocked APOL1 pore-forming function and ion channel conduction and reduced toxicity of APOL1 HR mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Podocyte injury, proteinuria, and glomerulosclerosis
“Risk genotypes overexpressed in podocytes play a crucial role in podocyte injury and correlate with disease severity.3,25 Although podocyte expression of G1/G2 APOL1 and engagement of downstream signaling mechanisms is necessary for glomerulosclerosis, there is a growing body of data for extra-podocyte roles of APOL1 risk variants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, there are no models of the slowly progressive, low proteinuria, chronic disease that accounts for the vast majority of human APOL1 kidney disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interferon-induced APOL1 expression and second hits
“Expression of APOL1 is regulated by cytokines (mostly by interferon), inflammation, hypoxia/ischemia, viruses, and nucleic acids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nongenetic second hits resulting in glomerular disease include high interferon states, viral infections (HIV and COVID-19), exposure to alpha, beta, or gamma interferon, and APOL1 overexpression,3,6,20,22,68 with high interferon states having the strongest evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most established systemic factors are viral infections (for example, HIV) and, more generally, systemic elevations in interferon levels. It is now apparent that APOL1 is expressed in an interferon-dependent manner55.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Kidney disease has also been reported in individuals with APOL1 risk variants after receiving therapeutic interferon138.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our results reveal that IFN-γ signaling simultaneously induces endothelial injury and primes renal cells for pyroptosis, suggesting a combinatorial mechanism for APOL1-mediated collapsing glomerulopathy, which can be targeted therapeutically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Downstream cellular injury pathways in experimental models
“Functions associated with G1 or G2 APOL1 overexpression in cells or mice include ion channel,26 actin cytoskeleton,51,60,61 or mitochondrial dysfunction62; endoplasmic reticulum stress3; reduction of global protein synthesis63,64; suPAR (soluble urokinase plasminogen activator receptor)-dependent activation of integrin65; activation of nucleotide sensors; and inflammation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cell and mouse models implicate endolysosomal and mitochondrial dysfunction, altered ion channel activity, altered autophagy, and activation of protein kinase R in the pathogenesis of APOL1-associated kidney disease; however, the relevance of these injury pathways to human disease has not been resolved.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Diagnostic definition: high-risk genotype with nondiabetic kidney disease
“AMKD is diagnosed when an individual with a high-risk APOL1 genotype develops nondiabetic kidney disease. There is no established glomerular filtration rate (GFR) cutoff to diagnose AMKD. Proteinuria (urine albumin to creatinine ratio >30 mg/g) is often present but is not a requirement for the diagnosis of AMKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Role of genotyping: definitive for risk alleles, not diagnostic of a specific disease
“Genetic testing is definitive for the presence of APOL1 risk alleles, although the presence of risk alleles is not prognostic or diagnostic of any specific kidney diseases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, for individuals, genotyping is an important clinical consideration given that the high-risk APOL1 genotypes are associated with significantly increased risk of CKD progression, and genotyping could inform risk stratification and frequency of follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delphi consensus: patients in whom APOL1-associated nephropathy should be considered
“A1. APOL1-associated nephropathy should be considered in all patients with kidney disease who have African ancestry, particularly when there is a family history of CKD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A2. Regardless of ancestry, APOL1-associated nephropathy should be considered in all patients with kidney disease and a family member with a confirmed APOL1 high-risk genotype” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A3. Clinical factors that are relevant to considering APOL1-associated nephropathy include hypertension, nondiabetic nephropathy, and rapid progression of CKD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A12. APOL1 testing is not common in routine clinical practice; it is carried out in only a few specialist centers, often as part of APOL1 research” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delphi consensus: testing and kidney biopsy if a treatment becomes available
“C3. If a treatment for APOL1-associated nephropathy becomes available, all patients suspected of having APOL1-associated nephropathy should be offered genetic testing with appropriate counseling” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C4. If a treatment for APOL1-associated nephropathy becomes available, all Black people (or those with sub-Saharan African ancestry) with CKD should be offered genetic testing with appropriate counseling” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C6. If a treatment for APOL1-associated nephropathy was available, a kidney biopsy should be performed to confirm the diagnosis in individuals with high-risk APOL1 genotypes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Misclassification as hypertension-attributed CKD
“Genetic testing for APOL1 in African ancestry patients with nephropathy is currently uncommon. As such, many patients with APOL1-associated nephropathy who present with subnephrotic proteinuria are misclassified as having unspecified CKD or hypertension-attributed CKD, although intensive BP control does not slow kidney disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many with West African ancestry who have hypertension and kidney disease who were previously labeled as hypertensive nephropathy are now recognized to carry 2 APOL1 risk alleles and have APOL1-contributed kidney disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KDIGO Controversies Conference: principles for APOL1 testing
“At population levels, there is insufficient evidence to guide recommendations for APOL1 routine testing or screening. There are no established treatments or treatment recommendations for APOL1 kidney disease, and APOL1 genotype results are not by themselves actionable for changing management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The individual has kidney disease OR is a prospective living kidney donor OR has a relative with an APOL1 high-risk genotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Appropriately qualified counseling is available to support voluntary and informed decision-making about testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In children with FSGS and CKD, APOL1 genotyping can inform prognosis, and early targeted testing for APOL1 genotype in infants and children could make possible early surveillance and intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Screening of asymptomatic individuals
“Screening of asymptomatic individuals in the US for high-risk APOL1 genotype is not currently recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, individuals with recent West African heritage who have nondiabetic CKD, proteinuria, or a family history of kidney disease may be offered APOL1 screening. All individuals should receive genetic counseling before and after APOL1 genetic testing and be advised about potential for increased cost of health insurance that may be associated with detection of a high-risk APOL1 genotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KDIGO 2024 CKD guideline: genetic testing in evaluation of cause
| Test category | Examples | Comment |
|---|---|---|
| Genetic testing | “APOL1, COL4A3, COL4A4, COL4A5, NPHS1, UMOD, HNF1B, PKD1, PKD2” | “Evolving as a tool for diagnosis, increased utilization is expected.” |
Genotype refinement: the p.N264K (M1) protective variant
“Therefore, this variant, based on prior functional and current genetic data, counters the toxic effect of the G2 allele, allowing the reclassifying of APOL1 high-risk individuals as non-high-risk if they carry the p.N264K missense variant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals with CKD with APOL1-HR genotypes, M1 was 4 times more frequent in those whose CKD was not due to FSGS or SRNS. Importantly, electronic health record and biopsy review identified an alternative, non-APOL1 cause for CKD in nearly all APOL1-HR-M1 cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with CKD with an APOL1-HR genotype and M1 should be evaluated for an alternative and potentially treatable cause of their CKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mendelian kidney disease in patients with high-risk genotypes
“Of 15,181 patients, 1035 (6.8%) had high-risk APOL1 genotypes. Among patients with recent genomic African ancestry, the prevalence of Mendelian kidney diseases was lower in those with high-risk APOL1 genotypes (9.6%; n = 91/944) compared with single risk APOL1 allele carriers (13.6%; n = 198/1453) and those with G0/G0 APOL1 genotypes (16.6%; n = 213/1281).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unexplained kidney failure in the United Kingdom
Living kidney donor evaluation
“Among transplant centers in the United States, in 1 survey,93 one-half of centers offered APOL1 testing. The KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors94 suggests that APOL1 genotyping may be offered to donor candidates with Sub-Saharan African ancestry. The British Transplantation Society95 recommends offering APOL1 genotyping (which is publicly funded by the United Kingdom National Health Service) as part of the assessment and communication of donor risk early in the evaluation of all potential donors of African heritage under 60 years old.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Healthy living donors who self-identify as Black people or of sub-Saharan or West African ancestry, who are otherwise approved for donation, should be counseled regarding the risk of future kidney disease from APOL1 G1 and G2 variants and the protective role of the N264K APOL1 variant and should also offered the option of testing (Supplementary Information, Case 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study found that the APOL1 genotype is a risk factor for reduced kidney function postdonation. These results suggest that all Black individuals who are living donor candidates in the US should undergo APOL1 genotyping for better risk stratification.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Key elements of consensus include the following: ask potential donors about African ancestry rather than race; make testing decisions only after discussion with donors; encourage disclosure of test results to blood relatives and organ recipients but do not require it; use test results to inform decision making, but never for unilateral decisions by transplant programs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Available tests: manufacturer-sponsored genotyping
Barriers to genetic testing
Clinical presentation - signs and symptoms
Symptom burden: often asymptomatic until advanced disease
“In terms of the clinical presentation and course of APOL1 nephropathies, we do not know the extent to which the annual risk of incident kidney disease differs over the life course of these individuals; the extent to which APOL1 kidney disease first manifests as microalbuminuria, macroalbuminuria or reduced eGFR” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Urinary findings: variable proteinuria, from subnephrotic to nephrotic range
“The typical traits of APOL1 kidney disease include recent (<10,000 years) African ancestry, variable proteinuria, interstitial fibrosis, and reduced kidney function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular signs: hypertension
“These variants, termed G1 and G2, are a frequent cause of kidney disease — termed APOL1 nephropathy — that typically manifests as focal segmental glomerulosclerosis and the clinical syndrome of hypertension and arterionephrosclerosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“APOL1 risk alleles were associated under an additive model with systolic blood pressure (SBP) and age at diagnosis of hypertension, which was 2 to 5 years younger in the APOL1 variant allele homozygotes (Cox proportional hazards analysis, p value for combined meta-analysis [pcom] = 1.9 × 10−5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“APOL1-associated estimated glomerular filtration rate decline was observed starting a decade later in life in the 30- to 39-year age range.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Kidney function: reduced eGFR at presentation
“Individuals with the APOL1 risk genotype tended to present at an older age and had significantly lower baseline eGFR, more segmental glomerulosclerosis and total glomerulosclerosis, and more tubular atrophy/interstitial fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at onset: adolescence and early adulthood in APOL1-associated FSGS
“As shown in Table 3, 70% of individuals with two APOL1 risk alleles experience onset of FSGS between the ages of 15 to 39 compared with 42% of carriers of 0 or 1 risk alleles (P = 0.0003, FET). Together these data support the idea that FSGS among APOL1 high-risk individuals is a distinct disease with earlier onset and tendency to present during the teenage years and early adulthood.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Acute presentation: acute kidney injury and nephrotic syndrome with collapsing glomerulopathy
“All but one patient presented with AKI, 17 had nephrotic-range proteinuria, and six had nephrotic syndrome. Fourteen (61%) patients required dialysis at presentation. Among 17 patients genotyped, 16 (94%) were high-risk APOL1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seventeen had nephrotic-range proteinuria when quantified, although only six had full nephrotic syndrome, largely due to the absence of edema.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seven had hematuria (defined as more than five red blood cells per high-power field; data available in n=21), and six had edema on physical examination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At biopsy day, mean serum creatinine was 6.5 mg/dl and mean urine protein-creatinine ratio was 11.5 g. Kidney biopsy specimens showed collapsing glomerulopathy, extensive foot process effacement, and focal/diffuse acute tubular injury.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All six patients had an APOL1 high-risk genotype. Five patients needed dialysis (two of whom died); one partially recovered without dialysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Histologic findings: FSGS, collapsing variant, and interstitial fibrosis
“There were differences in renal histology, particularly more collapsing variants in those with the risk genotype (P=0.02), although this association was confounded by age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The presence of 2 APOL1 risk variants (G1/G1, G1/G2, and G2/G2), referred to as high-risk genotype, substantially increases the risk of certain kidney diseases like FSGS, collapsing glomerulopathy (HIV and COVID associated), and severe lupus nephritis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Kidney failure requiring dialysis or transplantation
“Black individuals in the US with a high-risk APOL1 genotype are also more likely to develop hypertension-attributed ESKD, lupus nephritis–attributed ESKD, FSGS, and HIV-associated nephropathy compared with Black individuals who have a low-risk APOL1 genotype (Figure).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular disease
“A metanalysis showed no overall association between the presence of APOL1 risk variants and cardiovascular disease, suggesting that high-risk variants may not have a direct effect on cardiovascular disease independent from effects on kidney disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were also no significant associations between these variants and coronary heart disease, stroke, myocardial infarction, and heart failure when the conditions were considered individually. This study suggests that the APOL1 kidney-risk variants may not have a direct effect on cardiovascular disease separate from the effects of kidney disease itself.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no significant association between APOL1 genotypes and the composite CVD outcome in both unadjusted (HR=1.23; 95% CI: 0.83 to 1.81) and fully adjusted (HR=1.16; 95% CI: 0.77 to 1.76) models; however, in using an additive model, APOL1 high-risk variants were associated with increased cardiovascular mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In those without diabetes mellitus, APOL1 high-risk genotypes associated with greater risk of incident composite CVD (hazard ratio, 1.67; 95% confidence interval, 1.12–2.47) compared with those with APOL1 low-risk genotypes in multivariable adjusted models. This latter association was driven by ischemic strokes (hazard ratio, 2.32; 95% confidence interval, 1.33–4.07), in particular, those related to small vessel disease (hazard ratio, 5.10; 95% confidence interval, 1.55–16.56).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preeclampsia and pregnancy outcomes
“Fetal APOL1 genotype has been associated with maternal preeclampsia in preterm infants and with altered fetal growth in term infants.41 There is a clear health disparity in the prevalence and severity of preeclampsia in Black women compared with Hispanic or White women, apparently due at least in part to having an APOL1 high-risk genotype.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fetal APOL1 high-risk (HR) genotype was associated with preeclampsia, with odds ratios at EMC and UTHSC of 1.84 (95% CI 1.11, 2.93) and 1.92 (95% CI 1.05, 3.49), respectively. Maternal APOL1 HR genotype was not associated with preeclampsia. Mothers with the fetal APOL1 HR genotype had more cerebral or visual disturbances (63% versus 37%, p = 0.04).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of APOL1-mediated kidney disease
Humanistic burden and health-related quality of life
Health-related quality of life, anxiety, and depression in 78 adults and 29 children with primary FSGS and their care-partners
“This study cross-sectionally surveyed patients with primary focal segmental glomerulosclerosis (FSGS) and their caregivers/care-partners, in terms of physical and mental health-related quality of life (HRQoL) and work productivity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“78 adults and 29 children/adolescents with FSGS, with their care-partners/caregivers, were included. The median ages of adults and children/adolescents with FSGS were 44.5 and 12.0 years, respectively; 74.4% and 58.6% were female. Mean physical and mental SF-12 scores for adult patients were 41.9 (SD: 12.1) and 44.8 (10.2), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both SF-12 components for adult patients, the SF-12 mental component for care-partners, and all PedsQL item scores were worse compared to US general population estimates. Among adult patients, 28.2% reported at least moderate anxiety; 37.3% reported at least moderate depression. Compared to external controls, patients experienced significantly higher severity of anxiety (6.1 vs. 5.0) and depression (7.6 vs. 5.9; both p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with FSGS and their care-partners experience impairments to mental/physical HRQoL and work productivity, underscoring the need for effective FSGS therapies and care-partner support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life and health care costs in FSGS: review of three systematic literature reviews
“This supplement explores the burden of FSGS from a clinical, humanistic, and economic perspective, informed by the results of 3 systematic literature reviews. FSGS is associated with poorer quality of life and high health care costs, and these outcomes are correlated with disease severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
PROMIS health-related quality of life in 478 children and 1115 adults with primary glomerular disease
“We assessed the relationship between HRQOL and demographic and clinical variables in 478 children and 1115 adults at the time of enrollment into CureGN.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patient-reported edema consistently had the strongest and most robust association with each measured domain of HRQOL in multivariable analysis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Female sex, weight (particularly obesity), and estimated glomerular filtration rate were also associated with some, but not all, domains of HRQOL. Primary diagnosis, disease duration, and exposure to immunosuppression were not associated with HRQOL after adjustment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were substantial differences in racial distribution among the diagnoses, with black participants more likely to have FSGS and less likely to have IgAN or IgAV.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Racial and ethnic differences in health-related quality of life in glomerular disease
“Black adults missed work or school most frequently due to kidney disease (30 vs. 16–23% in the other 3 groups, p = 0.04), and had the worst self-reported global physical health (median score 44.1 vs. 48.0–48.2, p < 0.001) and fatigue (53.8 vs. 48.5–51.1, p = 0.002), compared to other racial/ethnic groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, these findings were not statistically significant with adjustment for socioeconomic status and disease severity, both of which were strongly associated with HRQOL in adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with glomerular disease enrolled in CureGN, the worse HRQOL reported by black adults was attributable to lower socioeconomic status and more severe glomerular disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and outcomes in 3837 adults with CKD
“Data from 3837 adult participants with mild to severe CKD enrolled in the prospective observational Chronic Renal Insufficiency Cohort and Hispanic Chronic Renal Insufficiency Cohort Studies were analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Younger age, women, low education, diabetes, vascular disease, congestive heart failure, obesity, and lower eGFR were associated with low baseline health–related quality of life (P<0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Low health–related quality of life across several subscales was independently associated with a higher risk of incident cardiovascular events and death but not associated with CKD progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility values by CKD treatment modality: meta-analysis of 190 studies
“In total, 190 studies reporting 326 utilities from over 56,000 patients were analysed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using time tradeoff as a referent instrument, kidney transplant recipients had a mean utility of 0.82 (95% CI: 0.74, 0.90).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The researchers found that the highest average utility was for those who had renal transplantation, 0.82, followed by the pre-dialysis group (0.80), dialysis patients (0.71), and, finally, patients receiving conservative care (0.62).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with late-stage CKD, treatment with dialysis is associated with a significant decrement in quality of life compared to treatment with kidney transplantation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life of caregivers of adults receiving maintenance dialysis: systematic review of 61 studies
“61 studies were identified that included 5,367 caregivers from 21 countries and assessed the impact on caregivers using 70 different scales.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Caregiver quality of life was poorer than in the general population, mostly comparable with caregivers of people with other chronic diseases, and often better than experienced by the dialysis patients cared for. Caregiver quality of life was comparable across dialysis modalities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported concern and worry after APOL1 genotyping in 200 Black adults
“Among 200 participants enrolled with completed 3-month follow-up as of January 2025, 17.5% (35/200) carried an APOL1 high-risk genotype (2 RRVs). At baseline, concern about kidney conditions was common: 39% reported being extremely concerned, 34% very concerned, 12% somewhat concerned, 10% a little concerned, and 6% not concerned at all.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“APOL1 high-risk genotypes were more common in those with an increase, compared to a decrease, in kidney concern at follow-up (29% vs 11%; P = 0.02). Worry related to having an APOL1 high-risk genotype declined over time, from 14% at baseline to 8% at 3 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Even among healthy individuals, such as living kidney donor candidates, APOL1 testing may evoke psychological distress and fear of kidney failure (7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Attitudes of African American living kidney donors toward APOL1 genetic testing
“Twenty-three donors participated in semi-structured interviews. Most (96%) reported that transplant centers should routinely offer APOL1 genetic testing to all AA potential donors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants believed that potential donors would experience psychological distress from learning they have two gene variants and could harm their recipients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
AMKD-specific health care resource utilization and cost studies
No evidence found.
Treatment use among 1332 patients with genetically confirmed AMKD in the United States: conference poster report
Medicare expenditures for people with kidney failure
Medicare fee-for-service expenditures for people with CKD
Health care resource utilization and costs in 844 patients with FSGS and matched controls
“Patients with FSGS (n = 844; first claim = index event) between April 2016 and December 2018 were matched on index date, age, sex, and race to non-FSGS controls (n = 1688).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean total medical costs were higher in FSGS ($59,753 vs. $8431 PPPY; P < 0.0001), driven by outpatient costs. Nephrotic range proteinuria was associated with higher all-cause inpatient, outpatient, and prescription costs versus nonnephrotic patients (all P < 0.0001), resulting in higher total costs ($70,481 vs. $36,099 PPPY; P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health care resource utilization and costs in FSGS by proteinuria and CKD stage: 9899 patients in a US claims and EHR database
“In this descriptive, noninterventional, retrospective cohort study, 9899 patients were identified between January 2016 and December 2020 in Optum de-identified Market Clarity Data” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was a consistent trend toward higher health care resource utilization and total costs with both chronic kidney disease progression (stage 1-5/kidney failure) and higher levels of proteinuria” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The observed prevalence of FSGS increased in the US and was highest among Black individuals. More advanced chronic kidney disease and higher levels of proteinuria were both associated with greater health care resource utilization and costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health care resource utilization and costs in FSGS-attributed kidney failure
“The FSGS cohort and Medicare Coverage and 1-year Medicare Coverage subgroups included 25,699, 6,340, and 5,575 patients, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Medicare Coverage and 1-year Medicare Coverage subgroups, 76.6% and 74.2% required inpatient admission, 69.9% and 67.3% visited the emergency room, and mean monthly health care costs were $6,752 and $5,575 in the year postindex, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drug costs may be underestimated because Medicare Part D coverage was not required; kidney acquisition costs were not available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health care resource utilization and costs in 2515 US veterans with FSGS
“The study included 2,515 veterans with FSGS who were followed for an average of 8.9 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 43.3% underwent dialysis and 5.8% had a kidney transplant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the first year post-index, 40% had an inpatient admission and 33% visited the emergency room; mean total healthcare cost per patient in the analysis was $36,543.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of APOL1-mediated kidney disease on families
Work productivity of care-partners and caregivers of patients with FSGS
“Additionally, 14–20% of care-partners and caregivers reported moderate to severe anxiety or depression. All employed groups reported high overall work impairment (15.0–30.6%), with adult patients and their care-partners reporting high FSGS-related activity impairment (37.8%; 17.3%, respectively), absenteeism (10.4%; 6.1%) and presenteeism (21.8%; 11.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work productivity and financial well-being of 674 caregivers of patients with CKD in seven countries, including the United States
“A total of 1303 patients and 674 caregivers were recruited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Work productivity and activity impairment were greatest among dialysis patients, a trend also observed among caregivers for patients on dialysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers for patients with CKD generally reported a higher degree of impairment than the matched general population for absenteeism (mean range 3.4–14.7% vs. 1.4–20.8%; difference: − 7.6% to 12.0%), presenteeism (mean range 28.7–41.3% vs. 8.5–19.8%; difference: 12.0–28.2%), work activities (mean range 22.5–33.6% vs. 7.8–19.1%; difference: 11.1–23.7%), non-work activities (mean range 34.5–49.8% vs. 11.2–21.0%; difference: 17.9–34.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The indirect burden of CKD extends beyond clinical costs to include significant financial and work productivity impacts on patients and caregivers, with greater challenges for patients on dialysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Loss of employer-sponsored health insurance after dialysis initiation in the United States
“18,408 in-center hemodialysis and peritoneal dialysis patients employed full-time at the time of dialysis initiation, with employer-sponsored health insurance three months post-dialysis, followed for loss of employer-sponsored health insurance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to patients receiving PD, patients receiving IHD without a fistula (HR, 1.26 [95% CI, 1.18–1.36]) and with a fistula (HR, 1.14 [95% CI, 1.05–1.24]) were more likely to lose employer-sponsored health insurance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Less than one quarter of working-age patients in the United States who began dialyzing between 1996 and 2013 were employed at dialysis initiation, and 38% of those employed six months prior to chronic dialysis were unemployed at dialysis start.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Direct and indirect costs to living kidney donors and their caregivers
“We collected cost data in the 12 mo following donation from 182 LKDs participating in the multicenter prospective Kidney Donor Outcomes Cohort (KDOC) Study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“LKDs missed 33 072 total work hours, 40% of which were unpaid and led to $302 175 in lost wages (mean $1660). Caregivers lost $68 655 in wages (mean $377). Although some donors received financial assistance, 89% had a net financial loss in the 12-mo period, with one-third (33%) reporting a loss exceeding $2500.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Family implications of APOL1 genetic testing
“Established guidance on disclosure of genetic test results to family members (cascade testing) should be followed. This typically involves provision of support and resources to a patient for passing on information to the family (if they choose) who may then seek counseling and testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“What are the impacts on individuals, families, and communities of donating and not donating kidneys from individuals with high-risk APOL1 genotypes (economic, psychological, societal), including consequences of continuing dialysis?” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Apolipoprotein L1 (APOL1) renal risk variants (RRVs) contribute to the increased risk of kidney disease among Black Americans, but use of genetic testing may be limited by patient concerns regarding clinical implications and effects on family.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
APOL1-specific family cost studies
No evidence found.
Economic impact of diagnostic testing
Genetic testing requirement for diagnosis
Manufacturer-sponsored no-cost APOL1 genotyping: Labcorp program
Manufacturer-sponsored no-cost APOL1 genotyping: Natera program
Manufacturer-sponsored no-cost APOL1 genotyping and genetic counseling: Arkana Laboratories program
Billing code for a commercial APOL1 genotyping test
List price or Medicare payment rate for APOL1 genotyping
No evidence found.
Cost of APOL1 genotyping of potential living kidney donors at one US center
“Since May 2017, all potential AA living kidney donors at our center underwent APOL1 genotyping early in the donor evaluation process.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One out of 26 potential donors had high-risk genotype and was therefore declined.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A crude cost analysis utilizing our sample suggested probable cost-effectiveness of APOL1 genotyping as it can prevent earlier onset of chronic kidney disease in AA donors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost as a barrier to genetic testing
“Barriers to widespread adoption of genetic testing include a lack of perceived benefit, lack of ease, difficulties in interpreting genetic variants, high cost, and the need for genetic counseling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When offering genetic testing, physicians should counsel patients on risks and potential implications of testing, which may include out-of-pocket expenses, data privacy concerns, emotional distress, and the impact of a positive test result on life and disability insurance applications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost considerations for population, pediatric, and donor APOL1 testing
“At population levels, evaluation of costs and potential benefits is important prior to investing in APOL1 testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Yet unnecessary testing would be costly and potentially anxiety-provoking.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“recommends offering APOL1 genotyping (which is publicly funded by the United Kingdom National Health Service) as part of the assessment and communication of donor risk early in the evaluation of all potential donors of African heritage under 60 years old.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Equipment costs of current APOL1 genotyping methods
“Current available genotyping methods rely on PCR and sequencing and are associated with high equipment costs, long turnaround times and bioinformatic data analysis, all of which can challenge their application in resource-limited settings or at the point-of-care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although APOL1 genotyping is typically performed using quantitative polymerase chain reaction or sequencing, these techniques require specialized technical expertise and costly equipment, resources that are often limited in sub-Saharan Africa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Renin-Angiotensin system inhibitors and blood pressure control
Renin-angiotensin system inhibitor recommendations: KDIGO 2024 CKD guideline
Supportive treatment for FSGS: KDIGO 2021 glomerular diseases guideline
Blood pressure control after a high-risk APOL1 genotype is confirmed: Delphi consensus
“After a patient with CKD is confirmed to have a high-risk APOL1 genotype, the clinician should:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inform the patient about other modifiable risk factors and renoprotective measures (lifestyle changes, BP control)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure goal and ACE inhibitor effects by APOL1 genotype in AASK
“In the AASK study, the primary outcome occurred in 58.1% of the patients in the APOL1 high-risk group and in 36.6% of those in the APOL1 low-risk group (hazard ratio in the high-risk group, 1.88; P<0.001). There was no interaction between APOL1 status and trial interventions or the presence of baseline proteinuria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“there was no significant interaction between APOL1 status and the randomized blood-pressure goal with respect to the progression of chronic kidney disease (P = 0.72 for interaction)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lack of significant interaction between APOL1 and treatment with an ACE inhibitor suggests that patients in the APOL1 high-risk group still benefit from this class of drugs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Strict blood pressure control and mortality by APOL1 genotype in AASK
“This included 682 participants with known APOL1 genotype (157 with high-risk genotype) previously assigned to either strict (mean arterial pressure [MAP] 92 mm Hg or less) versus usual blood pressure control (MAP 102-107 mm Hg) during the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the APOL1 high-risk group, risk of death was 42% lower comparing strict versus usual blood pressure control (0.58 [0.35-0.97]). In the APOL1 low-risk group, risk of death comparing strict versus usual blood pressure control was not significantly different (1.09 [0.84-1.43]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world use of RAAS inhibitors, SGLT2 inhibitors, and other drug classes in AMKD
Sodium-Glucose cotransporter-2 inhibitors
SGLT2 inhibitor recommendations: KDIGO 2024 CKD guideline
Dapagliflozin in biopsy-confirmed FSGS: DAPA-CKD prespecified analysis
“Of 104 participants with biopsy-confirmed FSGS, 45 were randomized to dapagliflozin and 59 to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary outcome occurred in 4 (8.9%) and 7 (11.9%) participants randomized to dapagliflozin and placebo, respectively [hazard ratio 0.62, 95% confidence interval (95% CI) 0.17, 2.17].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thereafter, mean rates of chronic eGFR decline with dapagliflozin and placebo were −1.9 (−3.0, −0.9) and −4.0 (−4.9, −3.0) mL/min/1.73 m2/year, respectively (difference 2.0, 95% CI 0.6 to 3.5, mL/min/1.73 m2/year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With respect to limitations, the DAPA-CKD study was not specifically designed to test our hypothesis in patients with FSGS, and the relatively small sample size of this subgroup limited the precision of estimates of treatment effects on the study endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No SGLT2 inhibitor data specific to APOL1 kidney disease
“Of note, much of the data on CKD progression due to APOL1 variants came before the widespread use of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dual angiotensin and endothelin receptor antagonists, and it is unclear whether such therapies influence disease development or progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nonsteroidal mineralocorticoid receptor antagonists
Nonsteroidal MRA recommendation in type 2 diabetes and CKD: KDIGO 2024 CKD guideline
Finerenone in nondiabetic CKD due to glomerular diseases: FIND-CKD prespecified subgroup
“Of 1584 participants, 903 (57.0%) had investigator-reported glomerular disease, including 416 (46.1%) with immunoglobulin A nephropathy, 215 (23.8%) with focal segmental glomerulosclerosis, and 90 (10.0%) with membranous nephropathy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The total eGFR slope up to 32 months was -3.50 mL/min/1.73 m2 per year with finerenone and -4.23 mL/min/1.73 m2 per year with placebo (0.73 mL/min/1.73 m2 per year difference; 95% CI, 0.22-1.24).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this exploratory analysis, treatment with finerenone slowed kidney function decline, reduced albuminuria, and lowered the risk of kidney failure or substantial loss of kidney function in patients with glomerular diseases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
AMKD with type 2 diabetes
Glucocorticoids and calcineurin inhibitors
Immunosuppression in primary and secondary FSGS: KDIGO 2021 glomerular diseases guideline
Treatment resistance in genetic forms of FSGS: KDIGO 2021 glomerular diseases guideline
Response to cyclosporine or mycophenolate mofetil with dexamethasone by APOL1 genotype: FSGS Clinical Trial
“The FSGS Clinical Trial involved 138 children and young adults who were randomized to cyclosporin or mycophenolate mofetil plus pulse oral dexamethasone with a primary outcome of proteinuria remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“APOL1 risk genotype did not affect response to either treatment regimen. Individuals with the risk genotype were more likely to progress to ESRD (P<0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At present, however, there are no data that would indicate that aggressive treatment with available agents retards progressive kidney function loss in these high-risk individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limits of glucocorticoids and calcineurin inhibitors in FSGS: review of burden
“Until recently, no medicines had been approved by the FDA or European Medicines Agency, with management focused on supportive care and proteinuria reduction.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Available treatments, such as glucocorticoids or calcineurin inhibitors, are limited in efficacy and safety.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Role of conventional immunosuppression in APOL1 kidney disease as a research question
Dual endothelin angiotensin receptor antagonists
Sparsentan indication, dosing, and REMS
Sparsentan versus irbesartan in FSGS: DUPLEX results in the label
Sparsentan versus irbesartan in FSGS: DUPLEX primary publication
“At 36 weeks, the percentage of patients with partial remission of proteinuria was 42.0% in the sparsentan group and 26.0% in the irbesartan group (P = 0.009), a response that was sustained through 108 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with FSGS, there were no significant between-group differences in eGFR slope at 108 weeks, despite a greater reduction in proteinuria with sparsentan than with irbesartan.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sparsentan in participants with APOL1 high-risk genotypes: DUPLEX post hoc analysis
“Finally, 14 patients (4%) had two APOL1 high-risk alleles, nine in the sparsentan and five in the irbesartan groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sparsentan treatment resulted in profound (approximately 50%) sustained reduction of UPCR in the patients with APOL1 high-risk genotypes, although the treatment effect versus irbesartan was not sustained during the second year of the treatment period (Figure 1C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CR occurred exclusively in sparsentan-treated patients among those with podocyte gene variants (8% versus 0%), in 18% versus 7% of patients with COL4A3–5 gene variants, and in 33% versus 20% of patients with APOL1 high-risk genotypes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Owing to the small sample size in each genetic subgroup, the result has limited analytic power” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Subgroup | Sparsentan, time-averaged change from baseline in UPCR, % (95% CI) | Irbesartan, time-averaged change from baseline in UPCR, % (95% CI) | Relative change, % (95% CI) | P value |
|---|---|---|---|---|
| APOL1 high-risk genotypes | “−54.3 (−76.6 to −10.9)”View highlighted excerpt for this quote | “−33.8 (−71.2 to 52.2)”View highlighted excerpt for this quote | “−27.3 (−78.1 to 141.2)”View highlighted excerpt for this quote | “0.57”View highlighted excerpt for this quote |
Antiretroviral therapy for HIV-associated nephropathy
Antiretroviral therapy recommendation: KDIGO 2021 glomerular diseases guideline
Antiretroviral therapy and HIVAN: KDIGO Controversies Conference on kidney disease in HIV
“The classic kidney disease of HIV infection, HIV-associated nephropathy (HIVAN), has become less common with widespread use of antiretroviral therapy (ART); however, there has been a simultaneous increase in the prevalence of other kidney diseases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Evidence from observational studies strongly supports the beneficial effect of early ART initiation on the risk of classic HIVAN.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the overwhelming benefit on survival, ART is recommended for all HIV-positive individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lifetime risk of HIVAN without antiretroviral therapy by APOL1 genotype
Kidney function after proteinuria onset in people with HIV and high-risk APOL1 genotypes
Dialysis
Timing of dialysis initiation: KDIGO 2024 CKD guideline
Initial kidney replacement therapy modality and age at treatment start in the United States
Age at hemodialysis initiation by APOL1 genotype
“African Americans carrying two copies of the G1 risk allele initiated chronic hemodialysis at a mean age of 49.0 ± 14.9 years, which was significantly younger than both subjects with one copy of the G1 allele (55.9 ± 16.7 years; P = 0.014) and subjects without either risk allele (61.8 ± 17.1 years; P = 6.2 × 10−7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Kidney transplantation
Preemptive transplantation: KDIGO 2024 CKD guideline
Transplant access for Black people with kidney failure in the United States
Allograft survival of kidneys from deceased donors with two APOL1 risk variants
“Combined analysis of 1153 DDKTs from AA donors revealed donor APOL1 high-risk genotype (HR 2.05; p=3×10−4), older donor age (HR 1.18; p=0.05), and younger recipient age (HR 0.70; p=0.001) adversely impacted allograft survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A competing risk analysis revealed that APOL1 impacted renal allograft survival, but not recipient survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Allograft survival by recipient APOL1 genotype
“Recipients carrying two APOL1 RA demonstrated lower graft survival compared to recipients with only one or none of APOL1 RA at 1-year posttransplant independently of other donor and recipient characteristics (Adjusted HR 3.2 [95% CI 1.0–10.4, p-value 0.05]). There was no significant difference in overall survival or graft survival after 3 years posttransplantation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Kidney function after living donation by APOL1 genotype: APOLLO
“Sixty-eight Black donors (15.3%) had APOL1 high-risk genotypes (G1/G1, G2/G2, or G1/G2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Black kidney donors with APOL1 high-risk genotypes had a higher risk of developing an eGFR of less than 45 mL/min/1.73 m2 than Black kidney donors without APOL1 high-risk genotypes (relative risk, 2.31; 95% CI, 1.16-4.61; P = .02) (after adjustment for predonation eGFR: relative risk, 1.91; 95% CI, 0.90-4.03; P = .09).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
FSGS recurrence and donor APOL1 testing: KDIGO 2021 glomerular diseases guideline
Implications for kidney transplantation: KDIGO 2025 APOL1 conference report
“In the United States, living donors with APOL1 high-risk genotypes more often develop advanced CKD post donation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“but recipients with high-risk APOL1 genotypes may also have reduced graft survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Agents must be shown to be safe in the transplant setting, including lack of interaction with immunosuppressive agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring for recurrent HIVAN after transplantation
“Given the strong association between the APOL1 risk variants and HIVAN, HIV-positive recipients of African descent and those who receive an allograft from a donor of African descent should be monitored for recurrent HIVAN.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary: limitations of current therapies
No therapy directed at APOL1-mediated kidney disease is approved; the KDIGO 2025 conference report states that there are “no established treatments or treatment recommendations for APOL1 kidney disease”, and a 2021 Delphi consensus agreed that “No specific treatment is currently available”. KDIGO guidelines recommend RAS blockade, blood pressure control, and dietary salt restriction for adults with FSGS, and an SGLT2 inhibitor for adults with CKD who meet the criteria the guideline specifies. In AASK, the primary kidney outcome occurred in 58.1% of participants with a high-risk genotype and 36.6% of those with a low-risk genotype (hazard ratio 1.88), with no interaction between APOL1 status and the randomized blood-pressure goal or antihypertensive drug. In the FSGS Clinical Trial, APOL1 genotype did not affect proteinuria response to cyclosporine or mycophenolate mofetil with dexamethasone, but participants with the high-risk genotype were more likely to progress to ESRD. In DUPLEX, sparsentan reduced proteinuria more than irbesartan without a significant difference in eGFR slope at 108 weeks, and the APOL1 high-risk subgroup comprised 14 participants. In a real-world cohort of 1,332 people with AMKD, 35.7% had a RAAS inhibitor fill or administration and 10.5% an SGLT2 inhibitor, and 45.7% had CKD stage 4 or 5.
No approved disease-directed therapy
“There are no established treatments or treatment recommendations for APOL1 kidney disease, and APOL1 genotype results are not by themselves actionable for changing management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A24. No specific treatment is currently available for patients with APOL1-associated nephropathy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is currently no specific treatment or management protocol for APOL1-associated nephropathy, and so, the clinical value of APOL1 testing in routine clinical practice has not been established.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression despite blood pressure control and RAS inhibition
“In conclusion, renal high-risk variants in APOL1 were associated with an increased risk of progression of chronic kidney disease among black patients, even among those with well-controlled blood pressure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, therapeutic options to retard disease progression are limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As such, many patients with APOL1-associated nephropathy who present with subnephrotic proteinuria are misclassified as having unspecified CKD or hypertension-attributed CKD, although intensive BP control does not slow kidney disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Residual disease burden and treatment utilization in real-world AMKD
Place in treatment, anticipated use, and care setting
Summary: anticipated place in therapy
Inaxaplin is investigational, and no labeled indication exists. The pivotal AMPLITUDE trial enrolls participants aged 10 to 65 years with two APOL1 variants (G1/G1, G2/G2, or G1/G2), a urine protein to creatinine ratio (UPCR) of 0.7 to less than 10 g/g, and an eGFR of 25 to less than 75 mL/min/1.73 m2, and excludes people with diabetes mellitus, a solid organ or bone marrow transplant, or another known cause of kidney disease. Inaxaplin is given as 45 mg once daily on top of standard of care. Vertex states that a positive AMPLITUDE interim analysis could form the basis for potential U.S. accelerated approval, and Vertex investor relations stated that AMPLITUDE could unlock a population of about 150,000 people in the U.S. and Europe. Vertex estimates approximately 100,000 further people with AMKD and comorbidities such as type 2 diabetes. The phase 2 AMPLIFIED study dosed 41 participants with modest proteinuria (cohort 1, n=23) or with type 2 diabetes (cohort 2, n=18), populations Vertex describes as not being studied in AMPLITUDE, and Fierce Biotech reported that an FDA label covering both cohorts would add about 100,000 people to the target population.
Use would depend on APOL1 genotyping. A Vertex-sponsored test describes a genetic test for two APOL1 risk variants as required for a definitive diagnosis of AMKD; trial eligibility used a Vertex-designated investigational assay, and the Vertex-sponsored Labcorp test states that it has not been cleared or approved by the FDA. A Delphi consensus panel agreed that nephrologists should counsel patients about APOL1 high-risk genotypes, order the test, and return results, and that if a treatment becomes available all patients suspected of having APOL1-associated nephropathy should be offered genetic testing with counseling. The KDIGO Controversies Conference report states that when treatments become available, “patient access to nephrologists with experience or knowledge of APOL1 kidney disease will be paramount”. In a U.S. real-world cohort of 1,332 people with AMKD, 45.7% had CKD stage 4 or 5 at a mean age of 45.6 years, 35.7% had at least one administration or fill of a RAAS inhibitor, and 10.5% of an SGLT2 inhibitor.
Target population of the pivotal AMPLITUDE trial
“APOL1 genotype of G1/G1, G2/G2, or G1/G2” (opens the source at this quote in a new tab)
“Solid organ or bone marrow transplant” (opens the source at this quote in a new tab)
“Uncontrolled hypertension” (opens the source at this quote in a new tab)
“History of diabetes mellitus” (opens the source at this quote in a new tab)
Manufacturer estimates of the AMKD population, including people with comorbidities
Populations evaluated beyond the pivotal trial: AMPLIFIED
Size of the target population by scope of a future label
Use in addition to standard of care
APOL1 genotyping as the gatekeeper to diagnosis and eligibility
Expert consensus on testing and treatment initiation once a treatment is available
“If a treatment for APOL1-associated nephropathy becomes available, all patients suspected of having APOL1-associated nephropathy should be offered genetic testing with appropriate counseling” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If a treatment for APOL1-associated nephropathy becomes available, all Black people (or those with sub-Saharan African ancestry) with CKD should be offered genetic testing with appropriate counseling” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If a treatment for APOL1-associated nephropathy becomes available, intervention should begin as early as possible in patients with APOL1-associated nephropathy on the basis of data from clinical trials” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If a treatment for APOL1-associated nephropathy was available, a kidney biopsy should be performed to confirm the diagnosis in individuals with high-risk APOL1 genotypes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting: nephrology
“Nephrologists should be responsible for counseling patients in their practice about the APOL1 high-risk genotypes as appropriate, ordering the APOL1 test, and returning results to patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“APOL1 testing is not common in routine clinical practice; it is carried out in only a few specialist centers, often as part of APOL1 research” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Current treatment and disease stage among people with AMKD
Heterogeneity of treatment effect
Summary: heterogeneity evidence for inaxaplin
The sources reviewed report no inaxaplin efficacy results stratified by APOL1 genotype. Of the 64 participants dosed in AMPLITUDE as of the 2024 abstract, 53.1% had the G1/G1, 37.5% the G1/G2, and 9.4% the G2/G2 genotype; efficacy results from that portion have not been published. The differences in response reported to date are by comorbidity and proteinuria level. In AMPLIFIED, the mean change in UACR at week 13 was -42.7% (95% CI -58.3% to -21.1%) in cohort 1 (modest proteinuria, most without diagnosed FSGS) and -17.3% (95% CI -36.3% to 7.2%) in cohort 2 (type 2 diabetes); the confidence intervals were generated post hoc, and the interval for cohort 2 includes no change. In the phase 2a study, the mean UPCR change was -47.7% in the 3 participants with nephrotic-range proteinuria and -47.5% in those with subnephrotic-range proteinuria, and 1 participant with 100% adherence had no reduction. In vitro, inaxaplin inhibited thallium flux in cells expressing G0, G1, and G2 APOL1; a 2026 abstract reports that inaxaplin partially reduced the cytotoxicity of full-length APOL1-G1 and did not rescue toxicity from a nuclear APOL1-G1 fragment produced by cathepsin S. For existing therapies, APOL1 genotype did not modify the effect of blood pressure target or ACE inhibitor treatment on CKD progression in AASK, and did not affect proteinuria response to cyclosporine or mycophenolate mofetil plus dexamethasone in the FSGS Clinical Trial; in AASK, strict blood pressure control was associated with 42% lower mortality in the high-risk genotype group only.
Inaxaplin: response by cohort in AMPLIFIED (modest proteinuria and type 2 diabetes)
Inaxaplin: response by baseline proteinuria range in the phase 2a study
Inaxaplin: APOL1 genotype distribution in the AMPLITUDE phase 2 portion
Inaxaplin: in vitro activity against G0, G1, and G2 APOL1
Inaxaplin: preclinical APOL1-G1 fragments resistant to channel inhibition
Genotype refinement: the p.N264K modifier of APOL1 G2
“The APOL1 p.N264K variant was recently found to genetically and almost completely negate the effect of G2 risk alleles to levels comparable to G0, and this observation has been replicated in subsequent studies, making APOL1 p.N264K the most robust genetic modifier of APOL1 G2 to date.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increase utilization of p.N264K in inclusion criteria of clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Determine the effects of conventional therapies for FSGS and other glomerular diseases in those with APOL1 high-risk genotypes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure target and ACE inhibitor by APOL1 genotype: AASK
“In the AASK study, the primary outcome occurred in 58.1% of the patients in the APOL1 high-risk group and in 36.6% of those in the APOL1 low-risk group (hazard ratio in the high-risk group, 1.88; P<0.001). There was no interaction between APOL1 status and trial interventions or the presence of baseline proteinuria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although baseline proteinuria was a major predictor of disease progression, it did not significantly modify the effect of APOL1 on progression (P = 0.16 for interaction) (Fig. 1B). In addition, there was no significant interaction between APOL1 status and the randomized blood-pressure goal with respect to the progression of chronic kidney disease (P = 0.72 for interaction) (Fig. 1C), nor was there a significant interaction between APOL1 status and the randomized antihypertensive medication with respect to progression (P = 0.72 for interaction)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lack of significant interaction between APOL1 and treatment with an ACE inhibitor suggests that patients in the APOL1 high-risk group still benefit from this class of drugs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality with strict blood pressure control by APOL1 genotype: AASK
“However, a significant interaction was detected between APOL1 risk group and blood pressure control strategy. In the APOL1 high-risk group, risk of death was 42% lower comparing strict versus usual blood pressure control (0.58 [0.35-0.97]). In the APOL1 low-risk group, risk of death comparing strict versus usual blood pressure control was not significantly different (1.09 [0.84-1.43]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other modifiers of APOL1-associated progression: AASK
“Sociodemographic factors and common risk factors for CKD progression do not seem to alter APOL1–related CKD progression. Additional investigation is needed to identify nontraditional factors that may affect the association between APOL1 and progressive CKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunosuppression response by APOL1 genotype: FSGS Clinical Trial
“APOL1 risk genotype did not affect response to either treatment regimen. Individuals with the risk genotype were more likely to progress to ESRD (P<0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The APOL1 risk genotype did not influence proteinuria responses to cyclosporin or mycophenolate mofetil/dexamethasone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline progression risk by diabetes status in proteinuric AMKD
Care management intervention strategies
Delphi consensus: counseling before and after APOL1 testing
“Patients should have a clear understanding of the purpose of the APOL1 test and the potential implications of the result before the test is taken” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When health care professionals discuss APOL1 testing with their patients, they should be honest and transparent about the current understanding of APOL1, take time to discuss APOL1 with patients, listen to their concerns, answer questions, and provide information sources that are balanced, easy to use and understand, and reliable” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a patient with CKD is confirmed to have a high-risk APOL1 genotype, the clinician should:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Encourage the patient to participate in clinical trials for which they are eligible” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inform the patient about other modifiable risk factors and renoprotective measures (lifestyle changes, BP control)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is no established best practice for counseling patients about APOL1 testing; further research is required to define best practice” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nephrology trainees need to be educated to be able to confidently deliver effective counseling to patients about APOL1 testing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delphi consensus: barriers to testing
“Clinicians’ lack of confidence in communicating the findings from APOL1 testing to patients in a clear and effective way that minimizes patient confusion and misunderstanding is a major barrier to APOL1 testing in patients with nephropathy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Low levels of trust in the medical establishment could be a barrier to APOL1 testing in the Black community” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lack of specific treatment and concerns regarding insurance reimbursement for genetic testing and potential discrimination on the basis of APOL1 genotype (e.g., life insurance, health insurance, job security) may be barriers to physicians educating patients about APOL1-associated nephropathy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delphi consensus: disease awareness and community education
“There are low levels of awareness of APOL1-associated nephropathy in the Black community” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nephrologists, primary care providers, nurses, community leaders, and patient networks all have an important role to play in educating Black patients with nephropathy about the APOL1 gene” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To improve awareness of APOL1 among the patient community, health care professionals should work with community leaders and community groups and should provide education in a setting that is familiar and comfortable for patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KDIGO Controversies Conference: requirements for operating APOL1 testing and community engagement
“For operationalizing genetic testing, the following are necessary: a validated test in a registered laboratory with appropriately trained staff; pre- and post-testing counseling; availability of co-designed educational material tailored to levels of health literacy; and a process for early surveillance and intervention, including in children. In high prevalence populations, community leaders, content experts, and faith leaders should be engaged to facilitate community education initiatives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Authentic community engagement is critical in designing and implementing APOL1 prevalence and research studies, testing in clinical care, as well as communicating how findings inform recommendations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Established guidance on disclosure of genetic test results to family members (cascade testing) should be followed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KDIGO Controversies Conference: principles for deciding on APOL1 testing
“Appropriately qualified counseling is available to support voluntary and informed decision-making about testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CKD care and screening are available AND APOL1 test results could change management (e.g., an effective treatment for APOL1 is available OR results could lead to increased surveillance for CKD OR results would inform risk/benefit evaluation in decision-making about living kidney donation).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KDIGO Controversies Conference: community outreach for clinical trial participation
“To raise awareness about CKD and APOL1 kidney disease as well as encourage participation in clinical trials, community outreach is required to develop, strengthen, and sustain relationships with trusted community leaders and partners.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As the understanding of and treatments for APOL1 kidney disease are further developed, engagement and education of communities and health care professionals, including those in primary care, will be key in improving patient health in all regions affected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic counseling and surveillance after a high-risk result
“All individuals should receive genetic counseling before and after APOL1 genetic testing and be advised about potential for increased cost of health insurance that may be associated with detection of a high-risk APOL1 genotype. When individuals are noted to have a high-risk genotype, physicians may consider more frequent screening for reduced GFR and proteinuria to identify AMKD at an early stage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KDIGO 2024 CKD guideline: genetic testing and counseling
Manufacturer-sponsored no-cost APOL1 testing program
Returning APOL1 results to patients with hypertension: randomized trial
“This pragmatic randomized clinical trial randomly assigned 2050 adults of African ancestry with hypertension and without existing chronic kidney disease in 2 US health care systems from November 1, 2014, through November 28, 2016; the final date of follow-up was January 16, 2018.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 3 months, the mean (SD) change in systolic blood pressure was significantly greater in patients with high-risk APOL1 genotypes vs those with low-risk APOL1 genotypes (6 [18] vs 3 [18] mm Hg; P = .004) and controls (6 [18] vs 3 [19] mm Hg; P = .01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer disease awareness campaign
Transplant center APOL1 testing policies: Delphi panel
“Key elements of consensus include the following: ask potential donors about African ancestry rather than race; make testing decisions only after discussion with donors; encourage disclosure of test results to blood relatives and organ recipients but do not require it; use test results to inform decision making, but never for unilateral decisions by transplant programs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary: expected outcomes
AMPLITUDE is designed to assess the effect of inaxaplin on kidney function and proteinuria. In the phase 2a study, proteinuria decreased by day 15 and continued to decrease through week 13. The phase 2a study reported a mean UPCR change of -47.6% (95% CI -60.0 to -31.3) at week 13; its authors cite data from nearly 30,000 participants in which a 30% albuminuria reduction corresponded to a 27% lower risk of a composite kidney endpoint, and state as a hypothesis to be tested that a longer treatment period may prevent or slow progression to end-stage kidney disease. The AMPLITUDE final analysis uses eGFR slope after two years as the primary efficacy endpoint and time to a composite of a sustained eGFR decline of 30% or more, end-stage kidney disease, or death as the secondary endpoint, assessed when approximately 187 composite outcomes have occurred. Across CKD trials, each 30% reduction in albuminuria was associated with a 27% lower hazard of the clinical endpoint (41 treatment comparisons, 29,979 participants) or a 19% lower hazard (48 trials, 85,681 participants), and a 0.75 mL/min/1.73 m2 per year greater treatment effect on total GFR slope with a 23.3% lower hazard. In FSGS, a partial remission defined as a 40% proteinuria reduction with proteinuria below 1.5 g/g was associated with less progression (hazard ratio 0.30 at month 8), and a 2025 review found that further work is needed to define a treatment effect short of complete remission as an endpoint. The only AMKD-specific analysis found, a preprint of 128 participants, estimated that a 50% reduction in UACR at 12 months was associated with a 28% lower risk of a kidney composite endpoint. The sources reviewed give no estimate of the delay in kidney failure expected with inaxaplin; Vertex states that people with AMKD reach kidney failure at a median age of 45 years.
Inaxaplin: proteinuria reduction and the hypothesized effect on progression
AMPLITUDE: endpoints that will measure clinical outcomes
Albuminuria change as a surrogate endpoint: meta-analysis of 41 treatment comparisons
“We identified 41 eligible treatment comparisons from randomised trials (referred to as studies) that provided sufficient patient-level data on 29 979 participants (21 206 [71%] with diabetes).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across all studies, with a meta-regression slope of 0·89 (95% Bayesian credible interval [BCI] 0·13-1·70), each 30% decrease in geometric mean albuminuria by the treatment relative to the control was associated with an average 27% lower hazard for the clinical endpoint (95% BCI 5-45%; median R2 0·47, 95% BCI 0·02-0·96).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria change as a surrogate endpoint: meta-analysis of 48 trials
“Here, in an individual participant data analysis of 48 randomized controlled trials (studies) involving 85,681 participants, we assessed the association between treatment effects on 6-month urinary albumin:creatinine ratio (UACR) change and the established clinical endpoint of kidney failure or doubling of serum creatinine concentrations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across all trials, each 30% reduction in the geometric mean of the UACR in the treatment group relative to the control group was associated with an average of 19% lower hazard for the clinical endpoint (95% Bayesian credible interval (BCI): 5-30%); median coefficient of determination (R2) = 0.66 (95% BCI: 0.06-0.98). There was no clear evidence that this association varied by CKD etiology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GFR slope as a surrogate endpoint: meta-analysis of 66 studies
“Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median R2=0.97 [95% Bayesian credible interval [BCI] 0.82 to 1.00]), and moderately associated with those on chronic slope (R2=0.55 [95% BCI 0.25 to 0.77]). There was no evidence of heterogeneity across disease. Our results support use of total slope as a primary endpoint for clinical trials of CKD progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“indicating that a 0.75 ml/min per 1.73 m2/year greater beneficial effect of the treatment on the total GFR slope is associated with an average 23.3% lower hazard ratio for the clinical end point (95% BCI 19.3% to 27.2%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria and GFR slope as joint surrogate endpoints
“The predicted probability of clinical benefit when considering both surrogates was determined primarily by estimated treatment effects on UACR when sample size was small (approximately 60 patients per treatment arm) and follow-up brief (approximately 1 year), with the importance of GFR slope increasing for larger sample sizes and longer follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
National Kidney Foundation, FDA, and EMA scientific workshop on surrogate endpoints
“In March 2018, the National Kidney Foundation sponsored a scientific workshop in collaboration with the FDA and EMA to evaluate changes in albuminuria or GFR as candidate surrogate end points.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We conclude that both early change in albuminuria and GFR slope fulfill criteria for surrogacy for use as end points in clinical trials for chronic kidney disease progression under certain conditions, with stronger support for change in GFR than albuminuria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Proteinuria remission and kidney survival in FSGS
“A novel definition of partial remission (40% proteinuria reduction and proteinuria<1.5 g/g) on the basis of receiver operating curve analyses of 89 patients was identified (Sensitivity=0.70; Specificity=0.77).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Propensity score–adjusted analyses showed the novel partial remission was associated with less progression at months 4 and 8 (month 4: hazard ratio, 0.50; P=0.01; month 8: hazard ratio, 0.30; P=0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 1 unit reduction in log-transformed urinary protein:creatinine ratio was associated with a 3.90 ml/year rise in eGFR (95% CI=2.01 to 5.79).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was an analogous relationship between time-varying proteinuria and time to end-stage kidney disease: the HR for ESKD or death per 1 unit reduction in log-transformed urinary protein-creatinine ratio was 0.23 (95% CI=0.12 to 0.44).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proteinuria endpoints in FSGS trials: Kidney Health Initiative review
“Available data support the use of complete remission of proteinuria in patients with heavy proteinuria as a surrogate endpoint for progression to kidney failure. While substantial treatment effects on proteinuria that are short of a complete remission may also predict the effect of a treatment on progression to kidney failure, further work is needed to determine how such an endpoint should be defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reasonably likely surrogate endpoints and accelerated approval
“We conclude that data support the use of proteinuria reduction as a reasonably likely surrogate end point for a treatment’s effect on progression to ESKD in IgAN. In the United States, reasonably likely surrogate end points can be used as a basis for accelerated approval of therapies intended to treat serious or life-threatening conditions, such as IgAN. The clinical benefit of products approved under this program would need to be verified in a postmarketing confirmatory trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria change as a surrogate endpoint in AMKD: real-world analysis (preprint)
“Recently, proteinuria has been accepted as a surrogate end point for clinical trials in focal segmental glomerulosclerosis (FSGS) ang IgA nephropathy. However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Real world data (RWD) analysis of 128 patients of African ancestry with APOL1 high risk genotypes, without diabetes, enrolled in the Million Veteran Program (MVP; n=109) or the biorepository at Vanderbilt University (BioVU; n=19), who had urine albumin-creatinine ratio (UACR) >= 420 mg/g (PCR~0.9 g/g) with a concurrent GFR value.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expected benefits of an APOL1-targeted treatment: expert consensus
“Important potential benefits of a treatment for APOL1-associated nephropathy becoming available include:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Slowing kidney disease progression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Extending life expectancy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reducing the incidence of ESKD in the Black population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reducing the number of people requiring a kidney transplant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote